Cue Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Collaboration revenue | $2,149 | $3,336 | $5,524 | $7,711 |
| Operating expenses: | ||||
| General and administrative | 4,939 | 2,867 | 12,792 | 10,564 |
| Research and development | 4,754 | 9,381 | 21,211 | 29,111 |
| Loss (gain) on fixed asset disposal | 51 | (97) | 51 | (97) |
| Total operating expenses | 9,744 | 12,151 | 34,054 | 39,578 |
| Loss from operations | (7,595) | (8,815) | (28,530) | (31,867) |
| Other income (expense): | ||||
| Interest income | 222 | 343 | 649 | 1,332 |
| Interest expense | (75) | (188) | (306) | (643) |
| Total other income, net | 147 | 155 | 343 | 689 |
| Net loss | $(7,448) | $(8,660) | $(28,187) | $(31,178) |
| Unrealized gain from available-for-sale securities | 1 | — | 1 | — |
| Comprehensive loss | $(7,447) | $(8,660) | $(28,186) | $(31,178) |
| Net loss per common share – basic and diluted | $(0.07) | $(0.17) | $(0.31) | $(0.62) |
| Weighted average common shares outstanding – basic and diluted | 100,869,349 | 51,229,701 | 90,271,072 | 50,292,983 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.